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The Medicaid Drug Rebate Program
Spending on outpatient prescription drugs accounts for a substantial share of total Medicaid expenditures—over $26 billion in
2006. Controlling drug expenditures is a challenge for states: rising prices, high drug utilization, and increases in the Medicaid
population all contribute to the growth of Medicaid outpatient
prescription drug expenditures. State Medicaid programs do not
purchase drugs directly; they reimburse pharmacies for covered
drugs dispensed to Medicaid beneficiaries. Each state defines
its pharmacy reimbursement formulas, which include the drug
ingredient cost plus a dispensing fee. States are not allowed to
use many cost containment tools (for example, closed drug formularies, tiered copayments, mandatory mail order) used by private purchasers to control drug spending, although they can use
other tools such as prior authorization and generic substitution.
Created by the Omnibus Reconciliation Act of 1990 (OBRA 1990),
the Medicaid Drug Rebate Program helps lower Medicaid spending on outpatient prescription drugs by ensuring states receive
discounts similar to those provided to private purchasers. While
complicated, technical, and at times controversial, the Rebate
Program has generated significant revenue for the states (and
the federal government) that helps offset Medicaid prescription
drug expenditures.

Rebat e Ag reem en t s
In order for pharmaceutical manufacturers to obtain Medicaid
coverage for their prescription drugs, they must sign a rebate
agreement with the Secretary of Health and Human Services (HHS) to provide rebates for those drugs when purchased
by Medicaid. Manufacturers pay the rebates directly to the
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states, and the rebates are shared with the federal government.
Approximately 550 drug manufacturers currently participate in
the rebate program. Once a manufacturer enters into a rebate
agreement, all of its prescription drugs are covered under Medicaid, subject to certain statutory exclusions.1

Bes t P ri c e a n d
Av er ag e M a n u fac t u rer ’ s P ri c e
Rebates are calculated for every outpatient prescription drug
that states cover under Medicaid fee-for-service. Manufacturers do not pay rebates for drugs provided in managed care settings. The rebate amounts pharmaceutical manufacturers must
pay are based on manufacturer-reported pricing data, namely
the best price and average manufacturer’s price (AMP) for each
drug, which are based on the prices and financial concessions
(for example, volume discounts, other rebates, etc.) available to
private purchasers. A drug’s best price and AMP are reported
to the Centers for Medicare & Medicaid Services (CMS) by the
manufacturer, but they are not publicly available.
• Best price is the lowest manufacturer price paid for a drug by
any purchaser (defined by the Medicaid statute as “any wholesaler, retailer, provider, health maintenance organization
(HMO), or nonprofit or government entity” with some exceptions2). A drug’s reported best price is required to reflect all
discounts, rebates, and other pricing adjustments.
• AMP is the average price wholesalers pay manufacturers for
drugs that are sold to retail pharmacies. (The statute defines
AMP as “the average price paid to a manufacturer for the drug
in the United States by wholesalers for drugs distributed to the
retail pharmacy class of trade.”) The transactions used to calculate AMP are to reflect cash discounts and other reductions
in the actual price paid.

Rebat es
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Rebates are paid on both brand name and generic drugs. The
brand name (known also as “innovator”) drug rebate is equal
to 15.1 percent of AMP per unit (15.1% AMP), or the difference
between AMP and best price per unit (AMP minus best price),
whichever is greater. The relationship between best price and
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AMP determines the size of the rebate; the closer best price is
to AMP, the more likely the rebate will be based on 15.1% AMP
(the minimum rebate amount). If a brand name drug’s AMP rises
faster than inflation, an additional unit rebate amount is calculated
based on the change in AMP compared with the consumer price
index. The rebate amount for generic drugs is 11 percent of AMP
per unit (11% AMP).
Rebate amounts are calculated and paid on a quarterly basis.
Manufacturers must report the best price and AMP for each
drug to CMS within 30 days of the end of each calendar quarter.
CMS uses the pricing information to calculate the unit rebate
amount for each drug and provides it to the states. Each state
determines its Medicaid utilization for each covered drug in
the quarter and reports this information to the manufacturer
within 60 days of the end of the quarter. The manufacturer
then computes and pays the rebate amount to each state within
30 days of receiving the utilization information. States report
rebate amounts received to CMS and share the rebates with the
federal government based on their federal medical assistance
percentage (FMAP).
Rebate amounts have risen along with the increases in Medicaid drug spending. As a percentage of Medicaid drug spending,
rebates increased from about 19 percent to 26 percent of Medicaid
drug spending between 2001 and 2005. This increase is likely due
to (i) a growing number of rebates calculated as the difference
between AMP and best price, rather than the minimum; and (ii)
a growing number of additional rebates due to drug prices climbing faster than inflation.

En dn ot es
1.

Section 1927(d) of the Medicaid statute identifies 11 categories of drugs
that states are allowed to exclude from coverage (for example, drugs
for anorexia, weight gain/loss; drugs to promote fertility; drugs for
cosmetic purposes or hair growth; barbiturates; benzodiazepines).

2. Exceptions to the best price include prices that are charged to certain
federal purchasers (sales made through federal supply schedule, singleaward contract prices of any federal agency, federal depot prices, and
prices charged to the Department of Defense, Department of Veterans
Affairs, Indian Health Service, and the Public Health Service), eligible
state pharmaceutical assistance programs and state-run nursing homes
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En dn ot es ( continued )
for veterans, and certain health care facilities, including those in underserved areas or serving poorer populations. Prices negotiated by
Medicare prescription drug plans or certain retiree prescription drugs
plans are also excluded from best price. Nominal prices—prices that
are less than 10 percent of AMP—also are excluded from best price.
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